A
Arnon Nagler
Researcher at Sheba Medical Center
Publications - 1435
Citations - 51740
Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor–Enriched Cord Blood, to Double Cord Blood Unit Transplantation
Patrick J. Stiff,Pau Montesinos,Pau Montesinos,Tony Peled,Efrat Landau,Noga R. Goudsmid,Julie Mandel,Nira Hasson,Esti Olesinski,Ela Glukhman,David Snyder,Einat Galamidi Cohen,Orna Srur Kidron,Dalia Bracha,Dorit Harati,Keren Ben-Abu,Etty Freind,Laurence S. Freedman,Yael C Cohen,Yael C Cohen,Liraz Olmer,Raya Barishev,Vanderson Rocha,Eliane Gluckman,Mary M. Horowitz,Mary Eapen,Arnon Nagler,Guillermo Sanz,Guillermo Sanz +28 more
TL;DR: In this multinational comparative study, transplanting expanded CD34+ stem cells from a portion of a single UCB unit, with the remaining unmanipulated fraction improved 100-day survival compared with DUCBT control patients while facilitating myeloid and platelet engraftment.
Journal ArticleDOI
Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT.
Sebastian Giebel,Myriam Labopin,Michael Potter,Xavier Poiré,Henrik Sengeloev,Gérard Socié,Anne Huynh,Boris V. Afanasyev,Urs Schanz,Olle Ringdén,Peter Kalhs,Dietrich W. Beelen,António Campos,Tamás Masszi,Jonathan Canaani,Mohamad Mohty,Arnon Nagler +16 more
TL;DR: Results suggest that outcomes of myeloablative autoHSCT and alloHSCT for patients with Ph+ ALL in first molecular remission are comparable and TBI-based regimens should be considered the preferable type of conditioning for Ph- ALL.
Journal ArticleDOI
Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Sandra Eder,Jonathan Canaani,Eric Beohou,Myriam Labopin,Jaime Sanz,William Arcese,Reuven Or,Juergen Finke,Agostino Cortelezzi,Dietrich W. Beelen,Jakob Passweg,Gérard Socié,Gunhan Gurman,Mahmoud Aljurf,Matthias Stelljes,Sebastian Giebel,Mohamad Mohty,Arnon Nagler +17 more
TL;DR: The results indicate that thiotepa-based conditioning may not be inferior to Cy/TBI for adult patients with ALL and that there was no significant difference between the two regimens in the incidence of either acute graft versus host disease (GVHD) or chronic GVHD.
Journal ArticleDOI
Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders
TL;DR: High-dose chemotherapy and radiation therapy may be successfully replaced by a more effective biologic tool, alloreactive donor lymphocytes, thus setting the stage for innovative therapeutic procedures for safer and more effective treatment of patients in need of BMT.
Journal ArticleDOI
Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT.
Giorgia Battipaglia,Ariane Boumendil,Myriam Labopin,Fabio Ciceri,Johanna Tischer,Matthias Stelljes,Gerhard Ehninger,Dietrich W. Beelen,Jürgen Finke,Maria Teresa Van Lint,Matthias Eder,Boris V. Afanasyev,Renato Fanin,Mohamad Mohty,Annalisa Ruggeri,Arnon Nagler +15 more
TL;DR: For R/R-AML, HLA-id sibling donors remain the gold standard, when available, due to higher mortality in Haplo without significant gain in disease control.